Rivus Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Charlottesvillevirginiafounded In 2019The Company Specializes In Mitochondrial Biology And Is Dedicated To Developing Innovative Treatments For Cardio Metabolic Diseasesparticularly Obesity Rivus Is Advancing Its Lead Programhu6A First In Class Small Molecule Therapy Aimed At Treating Various Cardio Metabolic Conditionsincluding Type 2 Diabetes And Heart Failurethe Company Is Also Focused On Creating Controlled Metabolic Acceleratorscmas Which Are Designed To Selectively Reduce Excess Fat By Utilizing Mitochondrial Uncouplingrivus Has Completed Phase I Studies And Is Conducting Phase Ii Clinical Trials To Evaluate The Safety And Efficacy Of Its Therapies With A Small Team Of About 8 Employeesrivus Pharmaceuticals Has Secured Significant Fundingincluding A $132 Million Series B Financing Round In 2022To Support Its Research And Development Effortsthe Company Encourages Patient Participation In Clinical Trials To Access Its Investigational Therapies
